Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7679442 | 0.76 | ENPP2 (0.50) | ENPP2PIK3R1PIK3CAIDO1HTT | |
| SCHEMBL3078778 | 0.74 | ENPP2 (0.58) | ENPP2BACE1KCNJ1KCNH2PIK3CA | |
| SCHEMBL6197480 | 0.71 | ENPP2 (0.50) | ENPP2KCNJ1KCNH2IDO1GRIA3 | |
| SCHEMBL483060 | 0.70 | PABPC1 (0.58) | PABPC1BACE1PIK3R1PIK3CACYP1A2 | |
| SCHEMBL6154461 | 0.70 | ENPP2 (0.54) | ENPP2KCNJ1KCNH2GRIA3GRIA4 | |
| SCHEMBL13928717 | 0.70 | ENPP2 (0.54) | ENPP2KCNJ1KCNH2GRIA3GRIA4 | |
| SCHEMBL1358998 | 0.70 | ENPP2 (1.00) | ENPP2KCNJ1KCNH2HTTGRIA3 | |
| SCHEMBL8326170 | 0.70 | ENPP2 (0.54) | ENPP2BACE1KCNJ1KCNH2GRIA3 | |
| SCHEMBL3038439 | 0.70 | ENPP2 (0.54) | ENPP2KCNJ1KCNH2GRIA3GRIA4 | |
| SCHEMBL3191645 | 0.70 | ENPP2 (0.54) | ENPP2KCNJ1KCNH2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665453-A1 | GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-08-28 | — | — | US | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4514802-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-03-05 | — | — | EP | disclosed |
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| CN-119219608-A | Polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | DUKE UNIVERSITY (US) | 2024-09-24 | — | — | US | disclosed |
| EP-1613610-A1 | BENZO 1,2,5 OXADIAZOLES AND BENZO 1,2,5 THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-10-20 | — | — | US | disclosed |
| EP-1517895-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004087684-A1 | BENZO[1,2,5]OXADIAZOLES AND BENZO [1,2,5]THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004000814-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-12-31 | — | — | WO | disclosed |
| US-6410547-B1 | (4-OXY-3-(ARYL)PHENYL)PYRIDINE FOR TREATMENT, PROPHYLAXIS OF INFLAMMATION, ESP. INFLAMMATORY OR OBSTRUCTIVE DISEASES OF THE AIRWAYS, E.G. FOR ASTHMA THERAPY; INHIBITORS OF PDE 4 ISOENZYME; DOWN REGULATE OR INHIBIT TNF-ALPHA RELEASE | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | MANLEY PAUL W (CH) | 2002-03-07 | — | — | US | disclosed |
| US-6288092-B1 | BIPHENYL PYRIDINES, BENZAMIDES AND PENYLCARBOXY COMPOUNDS USED AS SELECTIVE INHIBITORS OF PHOSPHODIESTERASE 4 ISOENZYME ACTIVITY AND DOWN REGULATORS OR INHIBIT TUMOR NECROSIS FACTOR RELEASE; ANTIHISTAMINES AND ANTIINFLAMMATORY | NOVARTIS AG (CH) | 2001-09-11 | — | — | US | disclosed |
| US-6258843-B1 | DRUGS AS ENZYME INHIBITORS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| US-6090817-A | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | NOVARTIS AG (CH) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | ENPP2 1282/4885PABPC1 705/4885BACE1 2500/4885 |
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | ENPP2 254/4885PABPC1 3710/4885BACE1 7/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | ENPP2 2013/4885PABPC1 1997/4885BACE1 1374/4885 |
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | IL4, PDE4A, PDE4C | ENPP2 446/4885PABPC1 3886/4885BACE1 612/4885 |
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | ENPP2 179/4885PABPC1 1650/4885BACE1 1508/4885 |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | HSF1, HSP90AB1, HSP90AA1 | ENPP2 1282/4885PABPC1 705/4885BACE1 2500/4885 |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | ENPP2 1282/4885PABPC1 705/4885BACE1 2500/4885 |
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, TGFBR2 | ENPP2 474/4885PABPC1 4244/4885BACE1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.